Cemiplimab for Kidney Transplant Recipients With Cutaneous Squamous Cell Carcinoma
1. There was no kidney rejection noted in the cemiplimab for kidney transplant recipients. 2. Cemiplimab was found to have ...
1. There was no kidney rejection noted in the cemiplimab for kidney transplant recipients. 2. Cemiplimab was found to have ...
1. In this Norwegian study, patients receiving organ transplants with cutaneous squamous cell carcinoma (cSCC) had higher rates of developing ...
1. After neoadjuvant treatment with celmiplimab, half of the patients were found to have a complete pathological response 2. Almost ...
Click to read this study in the Journal of the American Academy of Dermatology.
Click to read this study in the Journal of the American Academy of Dermatology.
Click to read this study in JAMA Dermatology.
Click to read this study in the Journal of the American Academy of Dermatology.
Click to read this study in the Journal of the American Academy of Dermatology.
Click to read the study in the Journal of the American Academy of Dermatology.
2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.
No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.
2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.
© 2021 2 Minute Medicine, Inc. - Physician-written medical news.
© 2021 2 Minute Medicine, Inc. - Physician-written medical news.